Reactions 1704, p86 - 2 Jun 2018 Thrombocytopenia: case report In a retrospective chart review of 27 women (aged 45 76 years), one woman was described [age not stated], who developed thrombocytopenia following treatment with carboplatin and paclitaxel for ovarian cancer [routes, duration of treatments to reaction onset and outcome not stated]. The woman, who had stage I/II ovarian cancer, started receiving treatment with paclitaxel 100 mg/m on days 1 and 11 along with carboplatin (AUC 6) every three weeks. She developed grade 3 thrombocytopenia. Author comment: "Stage I and II ovarian cancer patients who only received adjuvant divided-dose therapy, four required dose reductions, four had grade 4 neutropenia, and one had grade 3 thrombocytopenia." Kudlowitz D, et al. Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy naive women with high-grade epithelial cancers of Mullerian origin. Cancer Chemotherapy and Pharmacology 81: 847-851, No. 5, May 2018. Available from: URL: https://doi.org/10.1007/ s00280-018-3559-y - USA 803323454 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud